Stock Analiz

CalciMedica, Inc. CALC

Biotechnology: Pharmaceutical Preparations · IPO 2023 · data as of November 13, 2026

$1.21Market cap $8M
Open the interactive analysis →

CalciMedica, Inc. (CALC) is a healthcare company listed in the US with a market value of about $8M.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (3/5); the weakest is future growth (0/5).

Key numbers: a P/E of 0.3, a 5-year average ROIC of -268%.

About CalciMedica

CalciMedica is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2023. It was profitable in 0 of the last 7 years in our data. Its share count rose by 18152% over three years (dilution for shareholders).

Score: 1.2 / 5

Value2/5
Future growth0/5
Track record1/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)0.3
Forward P/E—
P/FCF—
P/S—
P/B2.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-218.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-268.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal year2025202420232022202120202019
Revenue———————
Net income-$30M-$14M-$34M-$8M-$36M-$28M-$37M
Free cash flow-$21M-$21M-$26M-$12M-$32M-$33M-$32M
EPS (diluted)$-1.97$-1.22$-7.66$-111.16$-441.57$-1371.74$-8729.49
Net margin———————
ROIC—-168.0%-368.8%——-24.9%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is CalciMedica’s P/E ratio?

About 0.3, based on the last twelve months of diluted earnings per share.

Does CalciMedica pay a dividend?

Not currently.

Is CalciMedica a good stock to buy?

We do not give buy or sell advice. CalciMedica scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.